Symphony Robotics’ patent-pending technology combines micro-robotic arms, real-time computer vision, and AI. | Source: Symphony Robotics
Symphony Robotics announced Tuesday that it licensed micro-robotic arm technology from Case Western Reserve University (CWRU).
Cleveland-based Symphony Robotics licensed CWRU’s novel, MRI-guided, magnetically actuated robotic platform. The technology navigates non-linear trajectories, enabling precise, micro-invasive surgeries with real-time guidance.
The company plans to advance the technology that combines micro-robotic arms, real-time computer vision, and state-of-the-art AI. Its initial focus centers around providing neurosurgeons with enhanced capabilities for complex microsurgical procedures. They target brain cancer — particularly glioblastoma multiforme (GBM) — and epilepsy.
Ultimately, Symphony says it hopes to reduce incision and craniotomy size to less than 4mm. This would mark a tenfold reduction compared to current clinical norms. The technology could enable extended, precise access to deep-seated lesions while protecting the surrounding tissue.
Register today to save 40% on conference passes!
The company built its ultra-maneuverable micro-robotic technology to leverage MRI capabilities and enable real-time guidance. Its product remains investigational. This technology is based on two proprietary advancements: leveraging the magnetic capabilities of MRI systems for non-linear navigation of the micro robotic arms and enabling real-time guidance with MRI’s high resolution imaging.
Symphony Robotics says it’s preparing for nationwide testing in collaboration with leading partner hospitals. This product is not available for clinical use and has not been cleared for use by the US FDA.
Symphony targets GBM
GBM is among the most aggressive and challenging brain cancers to treat, the company says. Existing surgical methods, such as craniotomies, are highly invasive, requiring large skull openings and posing significant risks. These include trauma to healthy brain tissue and delays in follow-up treatments such as radiation, chemotherapy, or drug delivery.
Other methods such as laser ablation only support a limited and partial treatment option. Symphony Robotics’ flexible, non-linear micro robotic arm aims to enable extended and precise access to deep-seated lesions while protecting surrounding eloquent tissue. This has the potential to improve outcomes and quality of life for GBM patients.
“Our technology will introduce unprecedented advancements in neurosurgery,” said Mordechai (Moty) Avisar, Symphony Robotics founder and CEO. “The potential to enhance surgical precision and improve patient outcomes is truly groundbreaking. Neurosurgeons will be able to perform highly targeted procedures on deep-seated pathologies through significantly smaller surgical openings—down to the micro level—while navigating complex, geometrically dispersed pathologies with greater safety and accuracy.”
Editor’s Note: This article was syndicated from The Robot Report’s sibling site MassDevice.
GIPHY App Key not set. Please check settings